Home > Quotes > SRCL > Guru Analysis > Kenneth Fisher
SRCL

Kenneth Fisher Guru Analysis for Stericycle, Inc.

$119.01
*  
0.31
0.26%
Get SRCL Alerts
*Delayed - data as of Jul. 11, 2014  -  Find a broker to begin trading SRCL now
Exchange: NASDAQ
Industry: Basic Industries
Community Rating:
View:    SRCL After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time

Assessments & Analysis Based on July 10, 2014 close price: $118.7

  for the Price/Sales Investor based on the criteria of Kenneth Fisher. Return to SRCL Guru Analysis

All Star Guru Scorecard

Source Go Chart %
Peter Lynch 0%
Benjamin Graham 43%
Validea 43%
Motley Fool 25%
David Dreman 57%
Martin Zweig 69%
Kenneth Fisher 30%
James P. O'Shaughnessy 50%



Detailed Analysis

Guru Score: 30%


PRICE/SALES RATIO: [FAIL]

The prospective company should have a low Price/Sales ratio. Non-cyclical stocks with Price/Sales ratios > 3 should never be purchased, however they can be held depending on the investor's risk aversion. SRCL's P/S ratio of 4.57 Based on trailing 12 month sales, is above 3, which is considered very unfavorable by this methodology. Based on this ratio, the stock is quite risky, however if risk does not bother you much, consider holding the stock until the P/S ratio approaches 6.


TOTAL DEBT/EQUITY RATIO: [FAIL]

Less debt equals less risk according to this methodology. SRCL's Debt/Equity of 77.50% is unacceptable, thus failing the test.


PRICE/RESEARCH RATIO: [PASS]

This methodology considers companies in the Technology and Medical sectors to be attractive if they have low Price/Research ratios. SRCL is neither a Technology nor Medical company. Therefore the Price/Research ratio is not available and, hence, not much emphasis should be placed on this particular variable.


PRELIMINARY GRADE: No Interest in SRCL At this Point

Is SRCL a "Super Stock"? NO


Price/Sales Ratio: [FAIL]

The Price/Sales ratio is the most important variable according to this methodology. The prospective company should have a low Price/Sales ratio. SRCL's Price/Sales ratio of 4.57 does not pass this criterion.


LONG-TERM EPS GROWTH RATE: [FAIL]

This methodology looks for companies that have an inflation adjusted EPS growth rate greater than 15%. SRCL's inflation adjusted EPS growth rate of 12.84% does not pass this test.


FREE CASH PER SHARE: [PASS]

This methodology looks for companies that have a positive free cash per share. Companies should have enough free cash available to sustain three years of losses. This is based on the premise that companies without cash will soon be out of business. SRCL's free cash per share of 3.78 passes this criterion.


THREE YEAR AVERAGE NET PROFIT MARGIN: [PASS]

This methodology looks for companies that have an average net profit margin of 5% or greater over a three year period. SRCL's three year net profit margin, which averages 14.18%, passes this criterion.

 
The names of individual investment advisors (i.e., the 'gurus') appearing ON THIS WEBSITE are for identification purposes ONLY. The names are used to identify the methodology as derived from the guru's published sources. The names of the individual gurus are not intended to suggest or imply any affiliation with or endorsement of, or even any agreement with the information displayed on this website personally by such gurus, or any knowledge or approval by such persons of the content on this website. All trademarks, service marks and trade names appearing on this website are the property of their respective owners, and are likewise used for identification purposes only.

The NASDAQ Stock Market, Inc. ("NASDAQ"), its affiliates, third party information providers, or any of these entities' officers, employees, directors, or agents have not: (1) passed on the merit of the information provided on this website or on any of these securities; or (2) endorsed or sponsored any of these securities. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED. The information contained on this website is provided for informational purposes only. See Full Disclaimer Below
See Full Disclaimer